Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 8/20 | 1.00 |
| ▸ | GRM2 | Q14416 | 4/20 | 1.00 |
| ▸ | GRM3 | Q14832 | 4/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | GRM8 | O00222 | 2/20 | 1.00 |
| ▸ | GRM6 | O15303 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | GRM5 | P41594 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | GRM1 | Q13255 | 1/20 | 1.00 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4835874 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL3125919 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL935371 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL481144 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2157698 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL179741 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL235442 | 1.00 | GRM4 (1.00) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL2916853 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL4835681 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 | |
| SCHEMBL7271016 | 0.88 | GRM4 (0.78) | GRM4GRM2GRM3CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11938106-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2024-03-26 | — | — | US | claimed |
| US-20230038631-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-02-09 | — | — | US | claimed |
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | claimed |
| US-11304917-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-04-19 | — | — | US | claimed |
| US-11938106-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230038631-A1 | TREATMENT OF TINNITUS USING GLUTAMATE RECEPTOR AGONISTS | NORTHEAST OHIO MEDICAL UNIV (US) | 2023-02-09 | — | — | US | disclosed |
| US-20220244263-A1 | METHODS FOR TREATING SMALL CELL NEUROENDOCRINE AND RELATED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2022-08-04 | — | — | US | disclosed |
| US-20220142960-A1 | Compositions and Methods for Treating Metabolic Disorders | VEROSCIENCE LLC | 2022-05-12 | — | — | US | disclosed |
| US-11304917-B2 | Treatment of tinnitus using glutamate receptor agonists | NORTHEAST OHIO MEDICAL UNIVERSITY (US) | 2022-04-19 | — | — | US | disclosed |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | RESILIO COMPANY LIMITED (JP) | 2017-05-11 | — | — | US | disclosed |
| US-9453000-B2 | Polycyclic compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2016-09-27 | — | — | US | disclosed |
| EP-2946792-A1 | THERAPEUTIC AGENT AND THERAPEUTIC METHOD RELATING TO 1,25D3-MARRS FOR NEUROLOGICAL DISEASE SUCH AS ALZHEIMER'S DISEASE& xA; | Resilio Company Limited (JP) | 2015-11-25 | — | — | EP | disclosed |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | RAMOT AT AVIV UNIVERSITY LTD. (IL) | 2010-06-10 | — | — | US | disclosed |
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | EISAI R&D MANAGEMENT CO., LTD (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2181992-A1 | POLYCYCLIC COMPOUND | Eisai R&D Management Co., Ltd. (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | EISAI R&D MANAGEMENT CO., LTD., (JP) | 2009-03-05 | — | — | US | disclosed |
| US-7365091-B2 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2008-04-29 | — | — | US | disclosed |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | ENOBIA PHARMA (CA) | 2006-12-21 | — | — | US | disclosed |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | ENOBIA PHARMA (CA) | 2006-06-22 | — | — | US | disclosed |
| US-6875764-B1 | Urea and thiourea compounds useful for treatment of coccidiosis | NEW PHARMA RESEARCH SWEDEN AB (SE) | 2005-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130537-A1 | CINNAMIDE COMPOUNDS FOR DEMENTIA | GRIN1, GRIN2A, GRIN3A | GRM4 22/4885GRM2 19/4885GRM3 23/4885 |
| US-20170129915-A1 | THERAPEUTIC AGENT FOR DISEASES ASSOCIATED WITH NERVE AXON DYSFUNCTION, INCLUDING THERAPEUTIC AGENT FOR ALZHEIMER'S DISEASE | GAP43, NGF, BDNF | GRM4 499/4885GRM2 453/4885GRM3 604/4885 |
| US-20060287280-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX | GLS, SUCNR1, PGD | GRM4 1241/4885GRM2 899/4885GRM3 1602/4885 |
| US-20060135480-A1 | Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex | GLS, SUCNR1, GCDH | GRM4 1196/4885GRM2 871/4885GRM3 1656/4885 |
| US-20100144868-A1 | Novel Neuroprotective Compounds and Uses Thereof | GRM2, GRIN1, GRM3 | GRM4 8/4885GRM2 1/4885GRM3 3/4885 |
| US-20090062529-A1 | MULTI-CYCLIC COMPOUNDS | APP, BACE1, PSEN1 | GRM4 1539/4885GRM2 489/4885GRM3 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.